Canaccord Genuity Rates Hinge Health (HNGE) buy, $76 Price Target

Canaccord Genuity maintains its buy stance on Hinge Health, Inc., keeping a $76 price target in place, a 9.48% upside from the current price.

By EarningsIQ Research Desk · Published Jun 15, 2026, 12:01 PM EDT · Updated Jun 22, 2026, 8:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

Canaccord Genuity rated Hinge Health, Inc. ($HNGE) "buy" with a $76 price target on June 15, 2026.

Since the rating, $HNGE is up 0.7% after 1 week, up 25.5% after 1 month and up 45.1% to date (from the $68.35 close on Jun 15, 2026).

HNGE Hinge Health, Inc.

$99.16 +117.65% year to date

Daily close · Oct 16, 2026

Key Points

Canaccord Genuity analyst Richard Close reiterated a buy rating on Hinge Health, Inc. (NYSE: HNGE) with a $76 price target on June 15, 2026.
Canaccord Genuity's $76 price target implies 9.48% upside from Hinge Health, Inc.'s ($HNGE) current $69.42 share price.
Hinge Health shares trade near $69.42, navigating a 52-week range between $30.08 and $107.00.
Insight Holdings Group recently reported large share transactions, including an acquisition of 530,982 shares on June 25, 2026, and a planned sale of 1,466,667 shares on June 29, 2026.

Get $HNGE trade alerts by text

We text you when insiders, Congress or big funds trade $HNGE. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Hinge Health, Inc. alert may contain errors. Disclosures

Canaccord Genuity Updates View on Hinge Health Shares

Canaccord Genuity kept its positive stance on Hinge Health, Inc. (NYSE: HNGE) on June 15, 2026, as analyst Richard Close reiterated a buy rating on the healthcare firm. The firm stayed firm on its $76 price target, reflecting its outlook on the company's growth in digital care delivery. The update comes as the broader analyst community reviews targets across the health information services sector.

12-month forecast

$HNGE price target

Hinge Health, Inc. daily closes and this analyst's $76 target. Not advice.

Hinge Health Stock Context and Market Levels

The stock changes hands around $69.42, holding ground between its 52-week low of $30.08 and its 52-week high of $107.00. Trading volume and sentiment keep the company in focus as investors weigh its position in technology-driven care for musculoskeletal conditions.

Recent Insider Transactions at Hinge Health

Insight Holdings Group reported multiple transactions in company shares during late June. On June 25, 2026, the group picked up 530,982 shares in a purchase transaction. Days later, on June 29, 2026, the group acquired another 1,466,667 shares. On the same date, June 29, 2026, Insight Holdings Group also disposed of 1,466,667 shares under a pre-arranged trading plan.

Wall Street Analyst Ratings and Price Targets

Other research firms have updated their outlooks on Hinge Health in recent months. On August 5, 2026, RBC Capital maintained an outperform rating while moving its target to $110.00 from $75.00. On the same day, Citizens kept a market outperform rating with a target of $107.00, up from $96.00. Truist Securities kept a buy rating on August 11, 2026, setting a $112.00 target from $85.00. Stifel maintained a buy rating on September 8, 2026, lifting its target to $115.00 from $96.00. Baird kept a neutral rating on September 22, 2026, moving its target to $90.00 from $85.00. Needham maintained a buy rating on September 30, 2026, raising its target to $115.00 from $97.00. Barclays maintained an overweight rating on October 12, 2026, with a target of $110.00 compared to $100.00 prior. Keybanc maintained an overweight rating on October 16, 2026, adjusting its target to $140.00 from $125.00. Overall, the stock carries a consensus buy recommendation with a mean price target of $112.13 across 16 analyst opinions.

What Hinge Health Does

Hinge Health, Inc. builds software and wearable devices to help manage musculoskeletal system care. The company focuses on tech solutions for acute injury, chronic pain, and post-surgical rehab through motion tracking and electrical nerve stimulation. It mainly sells its platform to self-insured employers looking to lower medical costs.

Looking Ahead for Hinge Health

Investors will watch for the company's next earnings report scheduled for November 2, 2026, to check revenue progress and margin trends. Analyst updates and further insider filings will continue to shape market sentiment in the coming months.